Sabinsa receives approval for New Health Claims on Curcumin C3 Complex® and Curcumin C3 Reduct® in Canada

Sabinsa’s Curcumin C3 Complex® and Curcumin C3 Reduct® received two significant health claims from Health Canada based on the new clinical studies on the respective products.

Curcumin C3 Complex®– Helps support healthy serum triglyceride levels

Shortly after being chosen for NutraIngredients’s “Best University Research Award” for a clinical study done in Iran, Sabinsa’s Curcumin C3 Complex® received approval from Health Canada for the health claim “supports healthy serum triglyceride levels, provides antioxidant,” applying to the combination of 500mg of Curcumin C3 Complex® and 5mg of BioPerine (Patented black pepper extract) to be taken twice daily. This claim is supported by a placebo controlled, randomized double blind cross over clinical study showing significant reduction in serum triglyceride concentration in obese subjects. In Canada the Curcumin monograph allows for traditional claims of “Antioxidants, Relief of Joint inflammation;” the new claim on the Curcumin C3 Complex® and BioPerine® combination adds more health benefits for consumers. Sabinsa holds multiple patents on both Curcumin C3 Complex® and BioPerine®

Curcumin C3 Reduct® – Provides Antioxidants

While studies on Curcuminoids have advanced knowledge of the role of curcumin in the body, it also revealed the transformations which curcumin undergoes in the body, including its conversion into tetrahydrocurcuminoids, which are widely accepted as most active metabolites of curcuminoids. Sabinsa’s Curcumin C3 Reduct® is a relatively new product, standardized to 95% of tetrahydrocurcuminoids, the active metabolite. Based on the studies available on Sabinsa’s Curcumin C3 Reduct®, NNHPD (Natural & Non prescription Health Product Directorate) in Canada approved the claim “Proves Antioxidants” for dosage of 100mg C3 Reduct twice daily. This is the first health claim for a Curcumin metabolite.

Sabinsa now holds 22 NPN on various ingredients in Canada including ZeaLutein®uc3 clear, Bacopin®, DigeZyme®, LactoSpore® and Garcitrin®.

“As the science on our natural products is increasing, we are determined to gain approval for new health claims supported by clinical studies for the Canadian market, where premarket approval for the health claims is required, thus validating our science” said Shaheen Majeed, Sabinsa Marketing Director.